Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcuta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2006-02, Vol.65 (2), p.257-260
Hauptverfasser:	Nikas, S N, Voulgari, P V, Alamanos, Y, Papadopoulos, C G, Venetsanopoulou, A I, Georgiadis, A N, Drosos, A A
Format:	Artikel
Sprache:	eng
Schlagworte:	28 joint count Disease Activity Score ACR Adalimumab Age Aged American College of Rheumatology Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - physiopathology Biological and medical sciences Blood Sedimentation C-Reactive Protein - analysis Concise Report Crohn's disease DAS 28 Diseases of the osteoarticular system Drug Administration Schedule Drug dosages Female Health Status Indicators Humans Immunomodulators Infliximab Joints - physiopathology Male Medical sciences methotrexate Middle Aged MTX Pharmacology. Drug treatments Platelet Count Rheumatism rheumatoid arthritis TNFα Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors tumour necrosis factor α
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!